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Genomics as a tool for guiding therapeutic intervention in transplant arteriopathy
The vascular response to injury entails differential regulation of gene expression. Accordingly, our laboratory has taken a genomic approach to studying the development of neointimal hyperplasia, using oligo microarrays alongside conventional histology (Figure 1 
Modulating intimal expansion by growth factor receptor inhibition
Growth factors are thought to play a central role in driving cell proliferation in the expanding neointima. Among other genes known to be rate-limiting for the development of transplant arteriopathy and chronic graft nephropathy, such as endothelin-1 and its receptor [8, 9] , our primary genomic screen identified the insulin-like growth factor-1 (IGF-1) and platelet-derived growth factor (PDGF) agonist-receptor pairs as potential targets for therapeutic intervention (Table 1) . Our group has previously shown that inhibition of any of these two growth-signalling pathways inhibited neointimal hyperplasia in rat models of arterial injury [10] [11] [12] ; these findings were recently corroborated by others [13] . Hence, the functional inhibition of these two growth factor receptors, achieved by inhibiting their expression, kinase activities or through the use of synthetic receptor antagonists, appears to have significant therapeutic potential.
Hormone receptor agonists: the key to refined control of vascular reactivity?
Endocrine regulation of inflammatory responses is a well-documented phenomenon and the vascular wall may be exquisitely sensitive to hormonal stimulation. Previous studies have shown that estrogen suppresses transplant arteriopathy in a rat transplant model [14] . We recently demonstrated that vascular expression of estrogen receptor beta (ERβ), but not ERα, increases acutely following endothelial denudation injury [15] and also in transplant arteriopathy [16] in the rat. ERβ mRNA and protein co-localised with both medial vascular smooth muscle cells and neointimal cells in affected vessels. Similar findings were documented in a baboon model of endothelial denudation injury [17] . Estrogen administration to ovariectomised rats suppressed neointimal hyperplasia but induced uterine hypertrophy. Conversely, administration of genistein, an ERβ-selective phytoestrogen, suppressed neointimal hyperplasia at doses below its receptor tyrosine kinase inhibitory activity, whilst having no effect on uterine tissue [15] . Thus, modulation of neointimal cell proliferation by activating ERβ may represent a highly targeted approach to managing neointimal hyperplasia.
Early results from our laboratory show that BIM23014C, a somatostatin analogue, also suppresses neointimal hyperplasia by specifically 
